Abbonarsi

Comparison of performance on Hospital Compare process measures and patient outcomes between hospitals that do and do not participate in Acute Coronary Treatment and Intervention Outcomes Network Registry–Get With The Guidelines - 12/05/16

Doi : 10.1016/j.ahj.2016.01.008 
Robin Mathews, MD a, , Gregg C. Fonarow, MD b, Shuang Li, MS a, Eric D. Peterson, MD, MPH a, John S. Rumsfeld, MD, PhD c, Paul A. Heidenreich, MD d, Matthew T. Roe, MD, MHS a, William J. Oetgen, MD, MBA e, James G. Jollis, MD a, Christopher P. Cannon, MD f, James A. de Lemos, MD g, Tracy Y. Wang, MD, MHS, MSc a
on behalf of the

National Cardiovascular Data Registry

a Duke Clinical Research Institute/Duke University Medical Center, Durham, NC 
b Ahmanson-UCLA Cardiomyopathy Center, University of California Los Angeles, Los Angeles, CA 
c Denver VA Medical Center, Denver, CO 
d VA Palo Alto Health System, Palo Alto, CA 
e American College of Cardiology, Washington, DC 
f Brigham and Women's Hospital, Boston, MA 
g University of Texas–Southwestern Medical Center, Dallas, TX 

Reprint requests: Robin Mathews, MD, Duke University Medical Center, 2400 Pratt Street, Durham, NC 27705.Duke University Medical Center2400 Pratt StreetDurhamNC27705

Riassunto

Background

Acute Coronary Treatment and Intervention Outcomes Network Registry–Get With The Guidelines (ACTION Registry–GWTG) was designed to measure and improve the treatment and outcomes of patients with acute myocardial infarction (AMI), yet it is unknown whether performance of Medicare Hospital Compare metrics and outcomes differ between hospitals participating versus those not participating in the registry.

Methods

Using 2007 to 2010 Hospital Compare data, we matched participating to nonparticipating hospitals based on teaching status, size, percutaneous coronary intervention capability, and baseline (2007) Hospital Compare AMI process measure performance. We used linear mixed modeling to compare 2010 Hospital Compare process measure adherence, 30-day risk-adjusted mortality, and readmission rates. We repeated these analyses after stratification according to baseline performance level.

Results

Compared with nonparticipating hospitals, those participating were larger (median 288 vs 139 beds, P < .0001), more often teaching hospitals (18.8% vs 6.3%, P < .0001), and more likely had interventional catheterization lab capabilities (85.7% vs 34.0%, P < .0001). Among 502 matched pairs of participating and nonparticipating hospitals, we found high levels of process measure adherence in both 2007 and 2010, with minimal differences between them. Rates of 30-day mortality and readmission in 2010 were also similar between both groups. Results were consistent across strata of baseline performance level.

Conclusions

In this observational analysis, there were no significant differences in the performance of Hospital Compare process measures or outcomes between hospitals in Acute Coronary Treatment and Intervention Outcomes Network Registry–Get With The Guidelines and other hospitals not in the registry. However, baseline performance on the Hospital Compare process measures was very high in both groups, suggesting the need for new quality improvement foci to further improve patient outcomes.

Il testo completo di questo articolo è disponibile in PDF.

Mappa


 Paul W. Armstrong, MD, served as guest editor for this article.


© 2016  Elsevier Inc. Tutti i diritti riservati.
Aggiungere alla mia biblioteca Togliere dalla mia biblioteca Stampare
Esportazione

    Citazioni Export

  • File

  • Contenuto

Vol 175

P. 1-8 - Maggio 2016 Ritorno al numero
Articolo precedente Articolo precedente
  • The China Acute Myocardial Infarction (CAMI) Registry: A national long-term registry-research-education integrated platform for exploring acute myocardial infarction in China
  • Haiyan Xu, Wei Li, Jingang Yang, Stephen D. Wiviott, Marc S. Sabatine, Eric D. Peterson, Ying Xian, Matthew T. Roe, Wei Zhao, Yang Wang, Xinran Tang, Xuan Jia, Yuan Wu, Runlin Gao, Yuejin Yang, CAMI Registry study group
| Articolo seguente Articolo seguente
  • Impact of genetic variants on the upstream efficacy of renin-angiotensin system inhibitors for the prevention of atrial fibrillation
  • Jason D. Roberts, Thomas A. Dewland, David V. Glidden, Thomas J. Hoffmann, Dan E. Arking, Lin Y. Chen, Bruce M. Psaty, Jeffrey E. Olgin, Alvaro Alonso, Susan R. Heckbert, Gregory M. Marcus

Benvenuto su EM|consulte, il riferimento dei professionisti della salute.
L'accesso al testo integrale di questo articolo richiede un abbonamento.

Già abbonato a @@106933@@ rivista ?

Il mio account


Dichiarazione CNIL

EM-CONSULTE.COM è registrato presso la CNIL, dichiarazione n. 1286925.

Ai sensi della legge n. 78-17 del 6 gennaio 1978 sull'informatica, sui file e sulle libertà, Lei puo' esercitare i diritti di opposizione (art.26 della legge), di accesso (art.34 a 38 Legge), e di rettifica (art.36 della legge) per i dati che La riguardano. Lei puo' cosi chiedere che siano rettificati, compeltati, chiariti, aggiornati o cancellati i suoi dati personali inesati, incompleti, equivoci, obsoleti o la cui raccolta o di uso o di conservazione sono vietati.
Le informazioni relative ai visitatori del nostro sito, compresa la loro identità, sono confidenziali.
Il responsabile del sito si impegna sull'onore a rispettare le condizioni legali di confidenzialità applicabili in Francia e a non divulgare tali informazioni a terzi.


Tutto il contenuto di questo sito: Copyright © 2025 Elsevier, i suoi licenziatari e contributori. Tutti i diritti sono riservati. Inclusi diritti per estrazione di testo e di dati, addestramento dell’intelligenza artificiale, e tecnologie simili. Per tutto il contenuto ‘open access’ sono applicati i termini della licenza Creative Commons.